Antibacterial treatment strategies in hospitalized patients: what role for pharmacoeconomics?
Antimicrobial agents continue to account for a significant portion of institutional pharmaceutical expenditures. Pharmacoeconomic analysis is a valuable tool in assessing antibacterial agents for their place in institutional formularies. This article reviews various types of pharmacoeconomic analyses, their respective limitations, and their roles in the antibacterial formulary decision-making process. We also discuss the current state of the antibacterial pharmacoeconomic literature, including the economic impact of antimicrobial resistance.
Goldman
Morton P
MP
Department of Pharmacy, Cleveland Clinic, Cleveland, OH 44195, USA. goldman@ccf.org
Nair
Radhika
R
D000900:Anti-Bacterial Agents / Q000191:economics* / Q000494:pharmacology / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003428:Cross Infection / Q000188:drug therapy* / Q000191:economics / Q000382:microbiology; D016527:Drug Costs; D024901:Drug Resistance, Multiple, Bacterial; D017850:Economics, Pharmaceutical; D005572:Formularies, Hospital as Topic; D006801:Humans; D010607:Pharmacy Service, Hospital / Q000191:economics*; D012720:Severity of Illness Index
D000900:Anti-Bacterial Agents